AU719837B2 - Pharmaceuticals based on papillomaviruses - Google Patents
Pharmaceuticals based on papillomaviruses Download PDFInfo
- Publication number
- AU719837B2 AU719837B2 AU53896/98A AU5389698A AU719837B2 AU 719837 B2 AU719837 B2 AU 719837B2 AU 53896/98 A AU53896/98 A AU 53896/98A AU 5389698 A AU5389698 A AU 5389698A AU 719837 B2 AU719837 B2 AU 719837B2
- Authority
- AU
- Australia
- Prior art keywords
- protein
- bpv
- lesions
- animals
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241001631646 Papillomaviridae Species 0.000 title claims description 35
- 239000003814 drug Substances 0.000 title description 9
- 230000003902 lesion Effects 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 38
- 241000701812 Bovine papillomavirus type 4 Species 0.000 claims description 30
- 102000037865 fusion proteins Human genes 0.000 claims description 17
- 108020001507 fusion proteins Proteins 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 150000001399 aluminium compounds Chemical class 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 229910052782 aluminium Inorganic materials 0.000 claims description 9
- 230000001681 protective effect Effects 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 3
- 108700031455 Bovine papillomavirus L2 Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- -1 aluminum compound Chemical class 0.000 claims 4
- 241001465754 Metazoa Species 0.000 description 73
- 208000003154 papilloma Diseases 0.000 description 37
- 238000002255 vaccination Methods 0.000 description 26
- 244000309466 calf Species 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 229960005486 vaccine Drugs 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 241000700605 Viruses Species 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 8
- 241000701822 Bovine papillomavirus Species 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 102000005720 Glutathione transferase Human genes 0.000 description 7
- 108010070675 Glutathione transferase Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 239000004411 aluminium Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 101000742340 Human papillomavirus type 16 Minor capsid protein L2 Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000003254 palate Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 210000003314 quadriceps muscle Anatomy 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000883306 Huso huso Species 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
- 229940001007 aluminium phosphate Drugs 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000701814 Bovine papillomavirus type 2 Species 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
- 206010023849 Laryngeal papilloma Diseases 0.000 description 1
- 101710157639 Minor capsid protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000004062 Tumor Virus Infections Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 231100000253 induce tumour Toxicity 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 201000000089 larynx squamous papilloma Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Description
i
AUSTRALIA
PATENTS ACT 1990
ORIGINAL
COMPLETE SPECIFICATION Name of Applicant: Address of Applicant: Actual Inventor(s): Cancer Research Campaign Technology Limited Cambridge House, 6-10 Cambridge Terrace, Regent's Park, London NW1 4JL, United Kingdom Maria Severia CAMPO and William Fleming Hoggan
JARRETT.
r Address for Service: DAVIES COLLISON CAVE, Patent Attorneys, 1 Little Collins Street, Melbourne, 3000.
Complete Specification for the invention entitled: Pharmaceuticals based on papillomaviruses The following statement is a full description of this invention, including the best method of performing it known to us: -1- -la PHARMACEUTICALS BASED ON PAPILLOMAVIRUSES The present invention relates to pharmaceuticals based on papillomaviruses.
Papillomaviruses induce a variety of lesions both in humans and in animals. Some papillomas, albeit benign, are themselves a clinical problem, such as laryngeal papillomas of children or penile papillomas of bulls and others are known to be a risk factor in the pathogenesis of cancer, as in the case of flat lesions of the cervix or penile condylomata in humans. Therefore both in human and veterinary medicine, antiviral pharmaceuticals against papillomaviruses eg for prophylactic use to protect against the establishment of a serious infection would be of major.
15 advantage.
Vaccination studies in humans present several problems. First of all experimentation is ethically unacceptable. Secondly, very limited amounts of virus are available as some lesions, in particular those of the S 20 cervix, do not produce viral progeny, and no in vitro system is yet available which allows vegetative replication of virus.
The production of viral proteins in bacteria and the use of synthetic peptides have circumvented this last problem and have allowed the ongoing analysis of the immune response to papillomavirus infection (see for instance Jenison et al, 1988 J. Virol, 62 p. 2115 and Tindle et al, 1990 J. Gen. Virol, 71 p. 1347.
Effective prophylactic vaccines, both natural (Jarrett et al, 1990 The Vet. Record, 126 p. 449) and genetically engineered (Pilachinski et al, 1986 Ciba Foundation Symposium Vol. 120 p. 136) have already been produced against bovine papillomaviruses, and regression of Shope papillomas has been achieved by vaccinating rabbits with tumour tissue extracts (Evans et al, 1962 J. Nat. Cancer Inst. 29 p. 277). The bovine system is an excellent model for papillomavirus induced diseases in the human and for medicaments against such diseases in humans given the several similarities between the bovine and human disease.
Namely multiple virus types with high lesion specificity (Jarrett et al, 1984 Virol. 136 p. 255), homology of genetic structure, and progression of some lesions to malignancy. The bovine system also presents several advantages in that cofactors in oncogenesis are known (Campo and Jarrett, 1986 In Papillomaviruses, Ciba Foundation Symposium 120, John Wiley and Sons p. 117) and, above all, direct experimentation is possible (Jarrett, 1985 In advances in Viral Oncology (Ed. G. Klein) 5 p.83).
Vaccination has been traditionally regarded as a prophylactic measure. Hosts are immunised against a pathogen and on subsequent exposure to the same organism, the infection is aborted at a preclinical stage. This is usually accomplished in virus infections by a neutralizing event directed at a superficial epitope on a structural protein. Virus-induced tumours such as papillomas often persist for long periods and are then, in a proportion of cases, rejected. The host may then be immune to
I
reinfection (Jarrett, 1985 supra). The nature of the rejection mechanism and its mediators is unknown, but it is advantageous to induce the rejection mechanism early in a tumour life cycle. In veterinary practice, it has been known for a long time that crude extracts of papillomas could sometimes, but by no means always, cause the rejection of homologous papillomas (Olson et al, 1959 Am.
J. Vet. Res. 21 p. 233, Evans et al, 1962 supra). These experiments were carried out before it was known that there were different types of papillomavirus in a species (Jarrett et al, 1984 supra; de Villier, 1989 J. Virol. 63 p. 4898), and that these are probably all immunologically type-specific (Jarrett et al. 1990 The Vet. Record 126 p.
473; Jenison et al, 1988 supra).
Papillomaviruses can infect and cause tumours in both cutaneous and mucous epithelia. In man and animals mucosal papillomas are often serious lesions which tend to run a prolonged course, as in the case of human laryngeal, genital and cervical papillomas (Steinberg, 1987 In the Papovaviride Vol. 2 (ed. N.P. Salzman and P.M. Howley) p.
265; zur Hausen, 1991 Virol. 184 p. These may be causal factors in the subsequent development of malignancies, as in the case of human papillomavirus
(HPV)
type 16-associated cervical carcinoma in women (zur Hausen, 1991 supra), and bovine papillomavirus (BPV) type 4associated alimentary cancer in cattle (Campo and Jarrett, 1986 supra). Clearly, there is an urgent need for pharmaceuticals against papillomavirus diseases.
r Despite recent limited success (Kreider et al, 1986 J.
Virol. 59 p. 369; Sterling et al, 1990 J. Virol. 64 p.
6305; Meyers et al, 1992 Science 257 p. 971; Dollard et al, 1992 Genes and Development 6 p. 1131), papillomaviruses are notoriously refractory to growth in cultured cells (Teichaman and LaPorta, 1987 In The Papovaviridae, Vol. 2 (ed. N.P. Salzman and P.M. Howley) p. 109) and the consequent lack of viral reagents has delayed the analysis of the immune response to the infection. The recent availability of recombinant technology has allowed the production of both early and late viral proteins in large amounts and in a purified form (Tindle et al, 1990 supra.; Jarrett et al, 1991 Virol. 184 p. 33; Ghim et al, 1992 Virology 190 p. 548; Stacey et al, 1992 J. Gen. Virol. 73 15 p. 2337) and thus has for the first time made it possible to study their immunising potential. It has already been S. shown that in cattle it is possible to use viruses and tumour extracts to induce both protection against, papillomavirus-induced cutaneous lesions (Jarrett et al, The Vet Record 1990 126 p. 473; The Vet Record 1990 126 p.
449) and to use recombinant proteins to induce both protection against and rejection of PV-induced cutaneous lesions (Virology 1991, 184 p. 33). The applicants now show that one can vaccinate in a practically significant fashion against papillomavirus for example the mucosal virus BPV-4, which in the field is a causative factor of squamous cell carcinoma of the upper alimentary canal (Campo and Jarrett, 1986 supra).
The present invention provides a pharmaceutical formulation for the prophylaxis of papillomavirus tumours or lesions selected from the group consisting of: a formulation which comprises a papillomavirus (PV) L2 protein or prophylactically effective fragment thereof and an aluminium compound, (ii) a formulation which comprises a bovine papillomavirus (BPV) L2 protein or prophylactically effective fragment thereof and an aluminium compound; (iii) a formulation which comprises a BPV-4 L2 protein or prophylactically effective fragment thereof and an aluminium compound; (iv) a formulation which comprises a BPV-4 protein or prophylactically effective fragment thereof and an adjuvant; a formulation which comprises a BPV-4 L2 protein or prophylactically effective fragment 15 thereof and an adjuvant; (vi) a formulation which comprises a BPV-4 protein or prophylactically effective fragment thereof and an aluminium compound; (vii) a formulation which comprises a PV L2 protein or prophylactically effective fragment thereof and an adjuvant; (viii) a formulation which comprises an HPV L2 protein or a prophylactically effective fragment thereof and an adjuvant; (ix) a formulation which comprises an HPV L2 protein or a prophylactically effective fragment thereof and an aluminium compound; a formulation which comprises an HPV-16 L2 protein or a prophylactically effective fragment thereof and ad adjuvant; (xi) a formulation which comprises an HPV-16 L2 protein or a prophylactically effective fragment thereof and an aluminium compound.
The pharmaceutical formulation may comprise a PV L2 protein or a prophylactically effective fragment thereof and an aluminium compound. The PV may be BPV. The BPV may be BPV-4.
The papillomavirus protein or prophylactically effective fragment thereof may be in the form of a fusion protein with a different co-protein. The co-protein may be glutathione-S-transferase.
The papillomavirus protein or prophylactically effective fragment thereof may be produced by recombinant DNA techniques.
The aluminium compound may comprise a mixture of aluminium hydroxide and aluminium phosphate. There may be 15 3% aluminium hydroxide and 2% aluminium phosphate. The aluminium compound may be aluminium gel.
S' Also provided is the use of a pharmaceutical 0 formulation as above in medicine for the prophylaxis of papillomavirus tumours or lesions Also provided is use of a PV L2 protein or prophylactically effective fragment thereof and an aluminium compound; or (ii) a BPV L2 protein or o. prophylactically effective fragment thereof and an aluminium compound; or (iii) a BPV-4 L2 protein or prophylactically effective fragment thereof and an aluminium compound; or (iv) a BPV-4 protein or prophylactically effective fragment thereof and an adjuvant; or a BPV-4 L2 protein or prophylactically 4* effective fragment thereof and an adjuvant; or (vi) a BPV-4 protein or prophylactically effective fragment thereof and an aluminium compound; or (vii) a PV L2 protein or prophylactically effective fragment thereof and an adjuvant; or (viii) an HPV L2 protein or a prophylactically effective fragment thereof and an adjuvant; or (ix) an HPV L2 protein or a prophylactically effective fragment thereof and an aluminium compound; or an HPV-16 L2 protein or a prophylactically effective fragment thereof and all adjuvant; or (xi) an HPV-16 L2 protein or a prophylactically effective fragment thereof and an aluminium compound in the production of a vaccine for the prophylaxis of papillomavirus tumours or lesions.
Also provided is a method of immunising a mammal 15 against papillomavirus tumours or lesions which comprises the administration of a pharmaceutical formulation as above in a therapeutically effective dosage.
Vaccines based upon the pharmaceutical formulations for prophylactic use as described above, can be prepared in accordance with methods well known in the art. Likewise, dosage rates can be determined according to known methods.
Attention is directed to New Trends and Developments in Vaccines, Editors A. Voller and H. Friedman, University Park Press, Bultimore, 1978 and to Remington's Pharmaceutical Science by E.W. Martin.
In order that the invention is more clearly understood, it will be further described by way of example only, and not by way of limitation, with reference to the a following figures.
Figure 1 shows results for vaccination with P-galearly (El, E2, E4 and E7) fusion proteins. A, animal No.
132 from group 3 (control. B, animal No. 146 from group 1 (pre-challenge vaccination). C, animal No. 139 from group 2 (post-challenge vaccination). Bar legend is in Figure.
D, pURE7. The recombinant plasmids containing El, E2 and E4 ORFs are not shown.
Figure 2 shows results for vaccination with p-gal-E7.
A, mean number of all tumours in vaccinated and control animals. B, mean number of stage 1 tumours. C, mean number of stage 2 tumours. D, mean number of stage 3 tumours. Squares, vaccinated animals; diamonds, control animals. In a repeated measurement analysis, P=0.02 in C 15 and 0.04 in D.
Figure 3 shows results for vaccination with E7+L2 and L2. A, pGEX recombinant plasmids. B-D, number of tumours in calves eleven weeks after challenge; B, group 1 (E7+L2 vaccine); C, group 2 (L2 vaccine); D, group 3 (control).
Materials and Methods All genetic manipulation procedures are carried out according to standard methods described in "Molecular Cloning", A Laboratory Manual eds. Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory Press, 1989 In the following it is described how the applicants produced recombinant BPV-4 peptides in Escherichia coli using pAT153 as a source of E7 and L2. Alternatively the invention may be put into effect by use of the L2 and E7 sequence information available from EMBL sequence database (accession no. X59063).
Calves Calves of mixed breed, approximately 12 weeks old, were obtained from papilloma-free sources. They were randomly assigned to groups and housed in separate, clean, well-ventilated pens in an isolation unit. All the calves were bled on arrival and at three to four weeks intervals thereafter for haematological analysis. The animals were cared for in complete accordance with the directives of the Home Office of Great Britain.
Production of recombinant BPV-4 peptides in Escherichia coli -Galactosidase E7 Fusion Proteins 15 The El, E2, E4 and E7 open reading frames (ORFs) of BPV-4 were cloned in the pUR plasmid series (Ruther and S* Muller-Hill, 1983 EMBO J. 2 p. 1791). The cloning of the El, E2 and E4 ORFs is not described.
The ORF encoding the E7 peptide was isolated by digesting the BPV-4 genome cloned in pAT153 (Campo M.S. et al, 1982 J. Gen. Virol. 63, p. 255) with BAMHI. The ORF encoding the E7 peptide was isolated as a BsrI fragment encompassing nucleotides (nts) 652-1249 and cloned in pUR 278 (Ruther and Mullter-Hill 1983 supra) via addition of BamHI linkers. The recombinant plasmid was transfected into Escherichia coli JM109 (Promega Ltd, Southampton, UK).
The bacteria were grown to mid-log phase in L-broth supplemented with 100 pg/ml ampicillin and induced to express the p-gal-fusion protein by addition of 100 pg/ml IPTG for 1-4hr. p-gal-E7 was prepared by suspending bacteria in lysozyme buffer (25% sucrose, 10mM MgCl 2 50 mM Tris HC1 pH 8.0, Img/ml lysozyme) containing 300 pg/ml DNase I. The fusion peptide was pelleted following cell lysis in 0.25% NP40, 0.125% deozycholate, 0.25M NaC1, Tris HC1 pH 7.2 and subsequent washes in 1.75M Guanidine HC1, 1M NaCi, 1% Triton X100.
(ii) Glutathione-S-transferase (GST) Fusion Proteins The E7 and L2 ORFs were cloned in pGEX (Smith and Johnson, 1988 Gene, 67 p.31).
The ORF encoding the E7 peptide was isolated as described above and cloned in pGEX 3X (Pharmacia Ltd, Milton Keynes MK9 3HP, UK) by blunt-end ligation (see Fig 9 15 3).
The ORF encoding the L2 peptide isolated by digesting Sthe BPV-4 genome cloned in pAT 153 (Campo et al 1982 supra) was obtained as a BamHI-EcoRI fragment encompassing nt 3987-5585 and cloned in its entirety in pGEX 2T (Pharmacia Ltd, Milton Keynes MK9 3HP, UK), and also as three Dde I fragments: a 5' end fragment (nt 4042-4610) in pGEX 2T; (ii) a middle fragment (nt 4610-4989) in pGEX 3X; and (iii) a 3' end fragment (nt 4989-5629) in pGEX 3X (see Fig. 3).
The GST fusion peptides represent the E7 protein from amino acids -21 to 98 (GST-E7); the L2 protein from amino acids 8 to 542 (GST-L2w) amino acids 11-200 (GST-L2a); amino acids 201-326 (GST-L2b); and amino acids 327-542 (GST-L2c).
Transformation and growth of bacteria and production of GST-fusion peptides were carried out as outlined for p-gal E7. The peptides were prepared in bulk by pelleting inclusion bodies from bacteria suspended in lysozyme buffer containing DNase I at 300 pg/ml and deoxycholate at Img/ml, followed by washing in 0.5% Triton X100/10mM EDTA, pH In all cases fusion peptides were suspended by boiling and sonication in 5% SDS, 5mM B-Mercaptoethanol, 50mM Tris HC1, pH 8.0 prior to vaccination. Yields were 2-3mg per gram wet weight of bacteria and 50-70% purity was routinely achieved.
Characterization of fusion proteins The p-gal-E7, GST-E7 and GST-L2 peptides were characterised by SDS-PAGE electrophoresis. The molecular weights of the fusion peptides were all in agreement with S 15 prediction. p-gal-E7 and GST-E7 were characterised immunologically using rabbit, bovine or murine antisera raised against p-gal-E7 or GST-E7 or GST-E7, in ELISA or Western blot analysis following absorption with the 9 appropriate bacterial protein. The immune sera reacted positively with both the homologous and the heterologous antigen, showing that the fusion proteins were .immunologically active and the sera were specific for E7 (see Table GST-L2 antigens were reactive in ELISA tests with homologous bovine sera, as was a p-gal L2 fusion protein, showing that GST-L2 was active immunologically and the sera were specific for L2 (see Table 1).
6.
9 9 9 9 9 6. S 9 9
S
S 6 *5 S 9* 6. 96. 12 S S Table* 1 FUSION PROTEINS ARE IMMUNOLOGICALLY ACTIVE blank no Ag no Ab 13-gal 1-gal:E7 GST GST-E7 Animal 5 pre-Immune 0.064 0.104 0.105 0.153 0.206 0.132 0.134 (P-gal-E7) Immune 0.058 0.192 0.174 0.718 2820.112 0.886 1-gal-L2 GST-L2 Animal 16 pre-Immune 0.064 0.149 0.124 0.15 0.231 0.284 0.317 (GST-L2) Immune 0.087 0.157 0.105 0.12 .1.512 0.724 2.694 Microtitre wells were coated with 500 pg/well of E7 fusion protein or 100 pg/well of L2 fusion protein. p-gal and GST were used in equivalent amounts. The wells were incubated overnight with the appropriate bovine sera and anti bovine IgG conjugated with Alkaline Phosphatase was added for 1 hour. Animal 5 is from exp 3, group 1; animal 16 is from exp 4, group 2.
13 Experimental design Vaccination with El, E2, E4, E7 early fusion proteins Eighteen animals were divided into three groups of six animals each. Each animal in group 1 was inoculated in the posterior left flank with 1 ml of PBS containing 1 mg of a cocktail of p-gal-early (El, E2, E4 and E7) fusion proteins emulsified in 1 ml of Freund's incomplete adjuvant (FIA); vaccination (boost) was repeated with a fortnight in the posterior right flank. Two weeks after the boost, all of the animals in each group were challenged in the palate (Jarrett et al, 1990 The Vet Record, 126 p. 473) with 1012 particles of BPV-4. Animals in group 2 were vaccinated as above two weeks after challenge, and boosted after a further two weeks. BPV-4 was purified from oesophageal 15 papillomas and typed as described previously (Campo et al, 1980 Nature, 286, p. 180) and the concentration of viral particles was estimated by the electron microscope assay (Jarrett et al, 1990 The Vet Record, 126 p. 449). Each animal was examined every three to four weeks, the papillomas were counted and their size measured as previously described (Jarrett, 1985 supra).
(ii) Vaccination with p-gal-E7 Nineteen animals were divided into two groups of eleven and eight animals each. The eleven calves in group 1 were each given a Img/lml suspension of the p-gal-E7 fusion protein emulsified in lml of FIA into the right quadriceps muscle. The vaccination was repeated four weeks later into the left quadriceps muscle (boost). Fourteen 14 days after the boost, all the animals in group 1 and 2 were challenged in the palate with 1011 BPV-4 particles at ten sites (10 10 particles per site). The animals were examined and the papillomas monitored as above.
(iii) Vaccination with GST-E7 and GST-L2 Forty-seven animals were divided into two groups of fifteen animals each (group 1 and 2) and one group of seventeen animals (group The calves of group 1 were each given a 2 ml suspension containing 1 mg of the GST-E7 fusion protein and 1 mg in total of the GST-L2 fusion peptides (the ratio of the GST-fusion peptides L2w:L2a:L2b:L2c was approximately 1:5:5:5) plus 2 ml of FIA into the right quadriceps muscle. The vaccination was repeated four weeks later into the left quadriceps muscle.
15 The calves of group 2 were each given 1 mg of the GST-L2 fusion proteins as described above. Two weeks after the 9* boost the animals in all three groups were inoculated in the palate at ten different places with a total of 101 BPV- 4 particles (1010 particles per site). The animals were examined and the papillomas monitored as above.
(iv) Vaccination with GST-L2 in aluminium gel Thirty-six animals were divided into three groups of twelve animals each. The calves of group 1 were each given i a 3 ml suspension containing 1 ml of GST-L2 fusion peptides at 1 mg/ml in the same ratio as above, 1 ml of 40 mM TRIS- HC1- 0.33% NaC1, and 1 ml of aluminium gel, made up of equal volumes of 3% aluminium hydroxide and 2% aluminium phosphate (Intervet UK Ltd, Cambridge Science Park, Cambridge CB4, UK). The vaccination was repeated four weeks later. The calves of group 2 were vaccinated as above, but with only 100 pg of L2 fusion peptides per animal. The calves of group 3 were the control. The challenge was as above.
Results Immunization with the E7 protein inhibits papilloma development and causes papilloma rejection E7 is the major transforming protein of BPV-4 in vitro (Jagger et al, J. Gen. Virol. 71 p. 3041) and is expressed throughout the different development stages of alimentary canal papillomas, pointing to its importance for the maintenance of the proliferative state also in vivo.
It is homologous to the oncoprotein E7 of human 15 papillomavirus type 16 (HPV-16) (Jagger et al, 1990 supra; Jackson et al, 1991 Molecular Carcinogenesis 4 pg. 382), the virus most often associated with squamouse cell carcinoma of the uterine cervix in women (zur Hausen, 1991 supra). Because of its pivotal role in cell transformation, E7 may be a target for cell-mediated immune responses leading to tumour rejection, both in BPV-4 and in HPV-16.
The applicants conducted two pilot experiments, which will be described briefly, and a third experiment with larger numbers of animals, which will be described in more depth.
In the first experiment, the applicants vaccinated calves with a cocktail of BPV-4 early proteins El, E2, E4 and E7, synthesized in bacteria as p-galactosidase fusion products (Ruther and Muller-Hill 1.983 supra; Jarrett et al, 1991 Virol., 184 p. 33). Six calves in group 1 were vaccinated before being challenged in the mouth with BPV-4, and six calves in group 2 were vaccinated after challenge.
Six control calves in group 3 were not vaccinated and were challenged with BPV-4 (see Table Four to six weeks after challenge, all the animals developed plaque-like lesions, which are stage la of alimentary canal papilloma development (Jarrett, 1985 supra). The lesions were confined to the injection sites. During the next twenty weeks, the lesions of the control animals grew in number and size, with secondary spread in the palate; and went through the well recognised stages of papilloma growth: raised plaques (stage lb), papillomas up to 2mm in length (stage 2) and papillomas bigger than 2mm (stage Stage 2 and stage 3 papillomas are the mature virus-producing tumours.
Table 2 VACCINATION STRATEGY Group Exp 1 Exp 2 Exp 3 Exp 1 (PR)E1-2-4-7(6) E7(6) E7(11) E7+L2(15) L2*(12) 2 (PS)E1-2-4-7(6) E2(6) nv(8) L2(15) L2**(12) 3 nv(6) nv nv(17) nv(12) The number of animals in each group is in parentheses. The animals were inoculated twice with 1 mg of protein, except in exp 5, group 2 where they received two inoculations of 100 pg each The adjuvant was FIA in all cases, except in exp 5 (L2* and were it was aluminium gel (Intervet UK, Ltd). In exp 1, PR indicates vaccine given pre-challenge and PS indicates vaccine given postchallenge; in exp 2-5, the vaccine was always administered pre-challenge nv. no vaccine.
Details of the papilloma developmental stages and their significance in the tumour life cycle have been described (Jarrett, 1985 supra). Approximately thirty weeks after challenge, natural involution of papillomas started to take place with decrease in size and number of lesions, and the animals were essentially papillomatosisfree by week fifty-four. The development of papillomas in a representative animal from this group is shown in Figure 1A. All the vaccinated animals, whether vaccinated before or after challenge, had approximately the same number of plaques as the control animals, indicating that the virus 20 was equally infectious and the calves equally susceptible to infection in the three groups. However most of the lesions in the vaccinated animals did not develop to full size, particularly in group 1, and were most rejected by 40-47 weeks after challenge, much earlier than in the control animals. The development of lesions in representative animals from the vaccinated groups are shown in figure lB and C. Two conclusions could be drawn from these results: that therapeutic vaccination was possible, 1 and that, within the time intervals used in this study, the time of vaccination relative to challenge was not critical.
To ascertain which one of the four early proteins was responsible for tumour regression, the applicants vaccinated six calves with p-gal-E7 and six with P-gal-E2 before challenge; six animals were the control group (see Table The E2-vaccinated animals did not behave any differently from the control group, while in the E7vaccinated calves most of the lesions did not grow beyond stage la and were rejected earlier than either in the control or in the E2-vaccinated animals (data not shown).
In the third larger experiment, eleven calves were vaccinated with p-gal-E7 before challenge and eight calves were kept as controls (see Table In this experiment plaques and raised plaques will be considered together as stage 1 lesions. As previously, all the animals developed the same number of plaques four weeks after challenge, confirming that they were all equally susceptible to infection (see fig. 2A). After ten weeks, the number of stage 1 lesions fell sharply in both groups, concomitant with the increase in the number of stage 2 lesions (see Figs. 2B and In the control group, the stage 2 lesions progressed to stage 3 lesions in the following ten weeks (see Fig. 2D) while the number of stage 1 lesions remained S 25 constant (see Fig 2B). There was no secondary spread, due to the smaller does of challenge virus (see Materials and Methods After five more weeks (twenty-five weeks post challenge), stage 3 and stage 2 papillomas started regressing (see Figs 2C and In the E7-vaccinated group, by week 10 after infection, the number of stage 2 lesions was higher and the number of stage 3 lesions lower than in the control group (see Figs 2C and Thirteen weeks post infection, the number of stage 2 papillomas decreased considerably, without concomitant increase in stage 3 papillomas (see Figs 2C and In the E7vaccinated animals therefore, progression from stage 2 to stage 3 lesions was being dramatically reduced and stage 2 papillomas were regressing before reaching full maturity.
The difference between the control and the vaccine group was observed not only when the number of stage 2 and stage 3 papillomas per group were considered, as in Fig. 2, but also when the percentage of stage 3 papillomas or the percentage of animals with stage 3 papillomas was considered (see Table 3).
In the three different experiments, a total of twenty-nine animals was vaccinated with E7. Twenty-two either did not develop mature papillomas or rejected 20 them earlier than the control animals. It may therefore be concluded that vaccination with E7 reduces tumour growth and induces premature tumour regression thus effectively providing a treatment for papillomas.
Vaccine E7 is effectively presented to the immune system Vaccination with E7 is accompanied by both a humoral and a cellular immune response to the vaccine. Both responses appear much earlier and have a greater amplitude in the vaccinated animals than in the control calves.
Whereas all of the vaccinated animals had serum antibodies to E7, serum antibodies to E7 were not in all of the control animals and some remained negative throughout the course of the experiment. Vaccine E7 is therefore presented to both effector arms of the immune system, while viral E7 is poorly presented. This may explain the efficacy of the therapeutic vaccine. The humoral and cellmediated immune response to E7 and the mapping of the Band T-cell epitopes will be presented in greater detail elsewhere.
Immunisation with the L2 protein prevents papilloma formation L2 is the minor capsid protein of papillomavirus.
Although the detailed molecular structure of the virion is not yet known, there is circumstantial evidence that a domain(s) of the protein is exposed on the surface of the virus (low titer virus-neutralizing L2 antibodies have been found in rabbits immunised with recombinant L2 protein .:"(Christensen et al, 1991 Virology 181 p. 572; Lin et al, 20 1992 Virology 187 p. 612)). The applicants have shown that S' vaccination with the L2 protein of the cutaneous papillomavirus BPV-2 induced early rejection of fibropapillomas of the skin, accompanied by infiltrates of immune cells in the regressing warts (Jarrett et al, 1991 25 Virology 184 p. 33).
L2 and E7 were produced in bacteria as glutathione-Stransferase (GST) fusion proteins (Smith and Johnson, 1988 supra). Fifteen animals were vaccinated with GST-L2, fifteen with GST-L2+GST-E7, and seventeen were kept as control (see Table All of the animals were challenged with equal amounts of virus from the same stock. The animals were examined four, seven and eleven weeks after challenge. In group 3, which had received no vaccine, 13 out of 17 calves developed lesions approximately four weeks after virus infection. These developed through the usual stages (see Table Eleven weeks after challenge, when the experiment was terminated, one of the four animals that were free of lesions at four weeks had only one stage 1 lesion and three had no lesions at all (see Table 4 and Fig. Of the fifteen animals in group 1 (L2+E7), two developed stage 1 lesions which subsequently disappeared, one developed stage 2 lesions, which were still present at the end of the experiment, and twelve did not develop any tumours at all (see Table 4 and Fig. In group 2 (L2) by the end of the experiment one calf had five stage 1 and one stage 2 lesions, and the remaining fourteen animals 0were completely tumour-free (see Table 4 and Fig. The 20 28 vaccinated animals with no tumours were still papillomafree forty-four weeks after challenge, whereas the control animals still had papillomas. Thus the L2 and L2+E7 eevaccines conferred a high degree of protection, an effect almost certainly due to the L2 protein, as the E7 vaccine has no protective effect by itself (see above). This was confirmed by a second L2 vaccination experiment, in which only the L2 peptides were used, the amount of antigen was decreased to 100 pg per inoculation per animal and the adjuvant was changed to aluminium gel (see Table Most animals in group 1 (11 out of 12) and all the animals in group 2 (12 out of 12) were completely protected from challenge and tumour-free, whereas 11 out of 12 control animals developed papillomas four weeks after challenge (data not shown). The L2 peptides therefore provide a powerful prophylactic vaccine. The results show that it is possible to reduce the dosage of L2 when administered in aluminium salts, while maintaining a strong prophylactic effect.
Thus the applicants have successfully achieved prophylactic and therapeutic immunisation against mucosal bovine papillomaviruses.
This has been accomplished in an animal host against its own natural pathogen. Cattle and their papillomaviruses have co-evolved and the immunological response observed in experimental conditions mimics the one observed in nature and is therefore biologically significant (Jarrett et al, 1991 Virology, 184 p. 33; 20 Campo, 1991 Cancer Cells, 3, p. 421).
The success obtained against the mucosal virus BPV-4 in the face of heavy challenge is particularly remarkable and of special relevance to the possible use of vaccines against genital papillomavirus in human subjects. There are several similarities between the BPV-4 and the HPV-16 systems. Both viruses infect mucous epithelia, giving rise to lesions that can neoplastically transform. In both viruses the major transforming functions, as defined in in vitro systems, are encoded by the E7 gene. Furthermore, the two E7 proteins show amino acid homology.
Virtually complete protection against BPV-4 infection was achieved by immunisation with the L2 protein.
Vaccination with the L2 protein of the cottontail rabbit papillomavirus (CRPV) has also been shown to have protective effect in the rabbit (Christensen et al, 1991 supra; Lin et al, 1992 supra), although to a more limited extent than in cattle. Taken together, these two sets of results suggest that L2 of HPV might have a similar effect in humans.
Immunisation with BPV-4 E7 induces rejection of established tumours which is accompanied by a strong cellular immune response. Vaccination of rats and mice with the HPV-16 E7 gene caused growth retardation and partial regression of tumours induced by HPV-16 transformed cells (Meneguzzi et al, 1991 Virology 191 P. 62-69; Chen et .al, 1991 PNAS 88, p.110), and, more recently, vaccination of mice with HPV-16 E7 elicited a delayed type hypersensitivity response specifically directed against the E7 antigen. Therefore E7 of different papillomaviruses can elicit the appropriate immune response to induce tumour rejection.
a.
S
a. S 9 9 9 9 0 .9.
999 9 9 99 9 .9.
*9 to: to 90 0.9 go 9 91 095 @99 *9V 24 Table 3 E7 VACCINE WEEKS POST
CHALLENGE
4 7 10 1 32 Lesion Stage Mean number of tumours in vaccinated group Mean number of tumours in control group Vaccinated a nimals wt Number of lesions in aanimals 1 1 2 3 11 0. 8. 0 2 .3 6.3 [1.2] 0 0 5.8 [1.3] 3.9 [1.3] 0 [0.3] 5] [0.2] [0.9] [0.1]
_I
1.1 2.1 5.4 2.5 1.8 4.4 3.1 3.9 1.8 [1.5] 8 0.1 [0.1] [1.1] 2.1 5.4 2.5 [1.11 [1.61 [1.51 [1.7] [1.8] 5 10 1 11 100] 0 0 8 7 [72] [64] [100] [18] [45] [91] [9] I I 4 6 3 3 5 3 3 0 [62] [37] 69 0 0 [100] 7 1 2 r 501 (75-i [371 [371 [62] [37] 96 89 1 JL~''J L~J 19 63 59] 43 [40] 3 [3] [94] [3] [17] [82] [0.9] I31 1 [70] [29] i t 64 [85] .1 10 1] [14] [20] 50] [29] [19] [47] [34] I I
S
S
0 5 i
S
9** *r 5
S
9*
S
.5 S 554I *5 *5 995. :0 00 0 01* 5* 55 9 Table 3 cont.
E7 VACCINE WEEKS POST CHALLENGE 17 21 25 29 Lesion Stage 1 2 3 1 2 3 1 2 3 1 2 3 Mean number of 2 5 1.2 2.5 2.6 1 0.3 3.8 0.2 1.1 2.6 0.3 tumours in [0.2] vaccinated group Mean number of 1.8 3 3.8 2 2.3 3.5 0 3.5 2.6 0.8 1.3 tumours in control [0.3] group Vaccinated animals 3 9 2 5 7 3 2 9 2 4 8 2 with lesions [27] [82] [18] [45] [64] [27] [18] [82] [18] [36] [72] [18] Control animals 4 5 3 4 4 4 0 5 4 3 3 3 with lesions [50] [62] [37] [50] [50] [50] [62] [50] [37] [37] [37) Number of lesions 22 55 13 27 29 11 3 42 2 12 29 3 in vaccinated [24] [61] [14] [40] [43] [16] [89] [27] [66] [7] animals Number of lesions 14 22 30 16 18 28 0 28 22 6 10 4 in control animals [21] [33] [45] [26] [29] [45] [56] [44] [30] [50] a: stage 1, plaque; stage 2, papillomas <2 mm; stage 3, papillomas >2 mm b: mean number of tumours in a group; SEM in parentheses c: number of animals with lesions in a group; percentages in parentheses d: total number of lesions in a group; percentages in parentheses 26 TABLE 4 E7 L2 and L2 Vaccines weeks post challenge 4 11 Lesion 1 2 3 1 2 31 2 3 stage Animal number GROUP 1 (E7+L2) 1 ~2 3 4 3-16- 4-15 GROUP 2 (L2) 16-26- 27 1 -51- 28-30 GROUP 3 (control) 31 5 6 -5 1- 32 1 12 6 6 5 8 33 5 2 8 -3 7- 34 6 2 7 2 6 4 35 36 I 1 37 11 r 13 1 6 4 38 39 ne 3 2 9- 40 7 4 8 -2 9 1 41 7 2 9 6- 42 ne 2 5 1 3 4 43 ne 3 3- 44 ne 11 10 ne 1 -3- 46 47 ne 5 7 -1 8ne =not examined; numbers represent lesions at each stage; lesion stag es as in Table 2. no lesions.
S 55
S.
qo ,S@ 5 4 0
S
S
~5 0'* S. S 0 0 .5
'S
Claims (7)
1. A method of preventing or lessening the occurrence or severity of lesions or tumours caused by papillomavirus infection, comprising administering to a mammal post-infection with papillomavirus a PV L2 protein or fragment thereof effective to provide a protective effect to lessen the occurrence and severity of lesions or tumours caused by PV infection and an aluminum compound; or (ii) a BPV L2 protein or fragment thereof effective to provide a protective effect to lessen the occurrence and severity of lesions or tumours caused by BPV infection and an aluminium compound; or (iii) a BPV-4 L2 protein or fragment thereof effective to provide a protective effect to lessen the occurrence and severity of lesions or tumours caused by BPV infection and an aluminum compound; or (iv) a BPV-4 protein or fragment thereof effective to provide a protective effect to lessen the occurrence and severity of lesions or tumours caused by BPV infection and an aluminum compound.
2. The method according to claim 1 which comprises administering a PV L2 protein or a fragment thereof and an aluminum compound.
3. The method according to claim 2 wherein said PV is BPV.
4. The method according to claim 2 wherein said PV is BPV-4. The method according to claim 1 wherein the papillomavirus protein or fragment thereof is in the form of a fusion protein with a different co-protein.
6. The method according to claim 5 wherein the co-protein is GST.
7. The method according to claim 1 wherein the papillomavirus protein or fragment thereof is produced by recombinant DNA techniques.
8. A method according to any one of claims 1 to 7 substantially as hereinbefore described o: I with reference to the Figures and/or Examples. DATED this 29th day of FEBRUARY 2000 Cancer Research Campaign Technology Limited SBy DAVIES COLLISON CAVE Patent Attorneys for the applicant
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU53896/98A AU719837B2 (en) | 1993-03-31 | 1998-02-11 | Pharmaceuticals based on papillomaviruses |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9306731 | 1993-03-31 | ||
GB939306731A GB9306731D0 (en) | 1993-03-31 | 1993-03-31 | Vaccines |
AU63817/94A AU6381794A (en) | 1993-03-31 | 1994-03-31 | Pharmaceuticals based on papillomaviruses |
AU53896/98A AU719837B2 (en) | 1993-03-31 | 1998-02-11 | Pharmaceuticals based on papillomaviruses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU63817/94A Division AU6381794A (en) | 1993-03-31 | 1994-03-31 | Pharmaceuticals based on papillomaviruses |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5389698A AU5389698A (en) | 1998-04-09 |
AU719837B2 true AU719837B2 (en) | 2000-05-18 |
Family
ID=25634155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU53896/98A Ceased AU719837B2 (en) | 1993-03-31 | 1998-02-11 | Pharmaceuticals based on papillomaviruses |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU719837B2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0133123A1 (en) * | 1983-07-25 | 1985-02-13 | Mgi Pharma, Inc. | Immunogens of papilloma viruses |
WO1993000436A1 (en) * | 1991-06-26 | 1993-01-07 | Cancer Research Campaign Technology Limited | Papillomavirus l2 protein |
AU2366692A (en) * | 1991-07-19 | 1993-02-23 | Csl Limited | Papilloma virus vaccine |
-
1998
- 1998-02-11 AU AU53896/98A patent/AU719837B2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0133123A1 (en) * | 1983-07-25 | 1985-02-13 | Mgi Pharma, Inc. | Immunogens of papilloma viruses |
WO1993000436A1 (en) * | 1991-06-26 | 1993-01-07 | Cancer Research Campaign Technology Limited | Papillomavirus l2 protein |
AU2366692A (en) * | 1991-07-19 | 1993-02-23 | Csl Limited | Papilloma virus vaccine |
Also Published As
Publication number | Publication date |
---|---|
AU5389698A (en) | 1998-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6020309A (en) | Pharmaceuticals based on papillomaviruses | |
US5866553A (en) | Polynucleotide vaccine for papillomavirus | |
Suzich et al. | Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. | |
AU662910B2 (en) | Papillomavirus L2 protein | |
Kirnbauer et al. | Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization | |
JP3958360B2 (en) | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation | |
AU688759B2 (en) | Production of human papillomavirus capsid protein and virus-like particles | |
US6458368B1 (en) | Attenuated microorganism strains expressing HPV proteins | |
KR20000067866A (en) | Polynucleotide vaccine formula for treating dog diseases particularly respiratory and digestive diseases | |
KR20000065256A (en) | Polynucleotide vaccine for the treatment of respiratory and genital diseases in pigs | |
WO1993020844A1 (en) | Papillomavirus e7 protein | |
Jagu et al. | A multimeric L2 vaccine for prevention of animal papillomavirus infections | |
US6153201A (en) | Oral immunization with papillomavirus virus-like particles | |
AU719837B2 (en) | Pharmaceuticals based on papillomaviruses | |
Moscarini et al. | Anti human papillomavirus vaccine: The checkmate to human papillomavirus? | |
AU5013099A (en) | Papillomavirus vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |